NYSE American - Delayed Quote USD

Lineage Cell Therapeutics, Inc. (LCTX)

Compare

0.6265

+0.0240

+(3.98%)

At close: January 30 at 4:00:00 PM EST

0.6320

+0.01

+(0.88%)

After hours: 7:56:54 PM EST

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks 15 hours ago

LCTX
+3.98%
Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

CARLSBAD, Calif., January 27, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of the second tranche of its previously announced registered direct offering of an aggregate of up to $66 million. The Company had previously received $24 million in gross proceeds at the closing of the first tranche in November 2024. Today, the Company received an addit

Business Wire 3 days ago

LCTX
+3.98%
Lineage Cell Therapeutics Issues Letter to Stockholders

CARLSBAD, Calif., January 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today published a letter to shareholders highlighting the company’s recent achievements and outlook for 2025.

Business Wire 24 days ago

LCTX
+3.98%
Lineage Cell price target lowered to $2 from $3 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $2 from $3 and keeps a Buy rating on the shares. The firm adjusted the company’s model for the new shares. The analyst says Lineage enters 2025 with “strong” operational progress, bolstered by a recent capital raise that extends its cash runway to support ongoing clinical trials and development programs. Key catalysts in the year ahead include pivotal updates from the OpRegen program for dry age-related macul

TipRanks 26 days ago

LCTX
+3.98%
Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Lineage Cell (LCTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks last month

LCTX
+3.98%
Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio?

We recently published a list of 7 new stock picks in Brad Gerstner’s portfolio. In this article, we are going to take a look at where Lineage, Inc. (NASDAQ:LINE) stands against other stock picks in Brad Gerstner’s portfolio. Gerstner Expects More M&As in New Term Strategists and investors are confident that the new administration will […]

Insider Monkey last month

LCTX
+3.98%
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif., November 21, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the first closing of its previously announced registered direct offering for the purchase and sale of up to an aggregate of 39,473,688 of Lineage’s common shares and accompanying warrants (the "common warrants") to purchase an aggregate of up to 39,473,688 of Lineage’s common share

Business Wire 2 months ago

LCTX
+3.98%
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lineage Cell (LCTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 2 months ago

LCTX
+3.98%
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

CARLSBAD, Calif., November 20, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it entered into definitive agreements with certain healthcare focused institutional investors and with Broadwood Partners, L.P. ("Broadwood"), an affiliate of Neal Bradsher, a member of Lineage’s board of directors, for the purchase and sale of up to an aggregate of 39,473,688

Business Wire 2 months ago

LCTX
+3.98%
Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Lineage Cell Therapeutics Inc (LCTX) extends its cash runway and progresses in key partnerships, despite facing regulatory and financial hurdles.

GuruFocus.com 2 months ago

LCTX
+3.98%
Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell (LCTX) delivered earnings and revenue surprises of 50% and 222.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

LCTX
+3.98%
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CARLSBAD, Calif., November 14, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

Business Wire 2 months ago

LCTX
+3.98%
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

MeiraGTx (MGTX) delivered earnings and revenue surprises of -14.89% and 4,264%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

MGTX

LCTX
+3.98%
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VYGR

LCTX
+3.98%
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

CARLSBAD, Calif., November 07, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, November 14, 2024, at 4:30 p.m. Eastern Time/1:

Business Wire 2 months ago

LCTX
+3.98%
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks 3 months ago

NVCR

LCTX
+3.98%
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

CARLSBAD, Calif., October 14, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the Maxim Group 2024 Virtual Healthcare Summit, in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research. Lineage’s fireside chat will be available for

Business Wire 3 months ago

LCTX
+3.98%
Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...

Despite a challenging biotech market, Lineage Cell Therapeutics Inc (LCTX) strengthens partnerships and maintains a strong cash position to support future growth.

GuruFocus.com 3 months ago

LCTX
+3.98%
ROG.SW
What Makes Lineage Cell (LCTX) a New Buy Stock

Lineage Cell (LCTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

LCTX
+3.98%
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

CARLSBAD, Calif., September 25, 2024--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will be presenting at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium, PSC-Derived Cell Therapies: Clinical Advances, NextGen Technologies, and the Path to Success. Mr. Culley

Business Wire 4 months ago

LCTX
+3.98%

Performance Overview

Return	LCTX	S&P 500
YTD	+25.30%	+2.78%
1-Year	-43.05%	+23.20%
3-Year	-58.51%	+36.99%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell (LCTX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Lineage Cell Therapeutics Announces Closing of Second Tranche of Previously Announced Registered Direct Offering

Lineage Cell Therapeutics Issues Letter to Stockholders

Lineage Cell price target lowered to $2 from $3 at D. Boral Capital

Down -43.14% in 4 Weeks, Here's Why Lineage Cell (LCTX) Looks Ripe for a Turnaround

Is Lineage (LINE) the Best New Pick in Brad Gerstner’s Portfolio?

Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering

Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering

Lineage Cell Therapeutics Inc (LCTX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Lineage Cell (LCTX) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Tops Revenue Estimates

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit

Lineage Cell Therapeutics Inc (LCTX) Q2 2024 Earnings Call Highlights: Strategic Alliances and ...

What Makes Lineage Cell (LCTX) a New Buy Stock

OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium

Performance Overview